• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.

作者信息

Catapano Alberico L

机构信息

Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy; and IRCCS MultiMedica, Sesto S. Giovanni, Via Milanese 100, 20099 Milan, Italy.

出版信息

Nat Rev Cardiol. 2018 Jan 16;15(2):75-76. doi: 10.1038/nrcardio.2017.221.

DOI:10.1038/nrcardio.2017.221
PMID:29336436
Abstract
摘要

相似文献

1
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.2017年血脂异常：致动脉粥样硬化脂蛋白作为治疗靶点。
Nat Rev Cardiol. 2018 Jan 16;15(2):75-76. doi: 10.1038/nrcardio.2017.221.
2
Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.根据基线非高密度脂蛋白胆固醇水平评估降脂治疗对死亡率的影响：一项荟萃分析
High Blood Press Cardiovasc Prev. 2019 Aug;26(4):263-272. doi: 10.1007/s40292-019-00330-8. Epub 2019 Jul 16.
3
Novel HDL-based therapeutic agents.新型基于高密度脂蛋白的治疗药物。
Pharmacol Ther. 2012 Jul;135(1):18-30. doi: 10.1016/j.pharmthera.2012.03.004. Epub 2012 Mar 23.
4
CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.CETP 抑制与高密度脂蛋白胆固醇：心血管风险或获益，亦或二者兼具？
Clin Pharmacol Ther. 2018 Aug;104(2):297-300. doi: 10.1002/cpt.1118. Epub 2018 Jun 27.
5
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.
6
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.脂蛋白比率：在心血管疾病预防中的生理意义及临床应用价值
Vasc Health Risk Manag. 2009;5:757-65. Epub 2009 Sep 18.
7
Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence.原发性人群中甘油三酯与心血管事件的关联：一项Meta回归分析及证据综合
Vasc Health Risk Manag. 2013;9:671-80. doi: 10.2147/VHRM.S52713. Epub 2013 Oct 31.
8
Novel concepts in HDL pharmacology.高密度脂蛋白（HDL）药理学的新观念。
Cardiovasc Res. 2014 Aug 1;103(3):423-8. doi: 10.1093/cvr/cvu141. Epub 2014 Jun 20.
9
Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.胆固醇酯转运蛋白抑制研究之旅：从实验室到临床
Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):360-6. doi: 10.1161/CIRCOUTCOMES.111.000014. Epub 2013 May 14.
10
Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.接受降血脂药物治疗的患者中低高密度脂蛋白胆固醇血症和高甘油三酯血症的患病率。
Arch Cardiovasc Dis. 2009 Jan;102(1):43-50. doi: 10.1016/j.acvd.2008.06.021. Epub 2009 Jan 25.

引用本文的文献

1
High-density lipoproteins may play a crucial role in COVID-19.高密度脂蛋白可能在 COVID-19 中发挥关键作用。
Virol J. 2022 Aug 23;19(1):135. doi: 10.1186/s12985-022-01865-4.
2
Role of cholesterol and sphingolipids in brain development and neurological diseases.胆固醇和神经鞘脂在大脑发育和神经疾病中的作用。
Lipids Health Dis. 2019 Jan 25;18(1):26. doi: 10.1186/s12944-019-0965-z.

本文引用的文献

1
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.男性原发性低密度脂蛋白胆固醇水平升高至 190mg/dL 或以上的心血管疾病一级预防中降低低密度脂蛋白胆固醇：来自 WOSCOPS（苏格兰西部冠状动脉预防研究）5 年随机试验和 20 年观察随访的分析。
Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6.
2
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.PCSK9 抑制剂依洛尤单抗降低 LDL-胆固醇水平的临床疗效和安全性：FOURIER 试验的预先设定的次要分析。
Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.
3
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.载脂蛋白 AI 模拟肽（Anacetrapib）在动脉粥样硬化性血管疾病患者中的作用。
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.
4
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.抗前蛋白转化酶枯草溶菌素 9 型疫苗 AT04A 可降低 APOE*3Leiden.CETP 小鼠的总胆固醇、血管炎症和动脉粥样硬化。
Eur Heart J. 2017 Aug 21;38(32):2499-2507. doi: 10.1093/eurheartj/ehx260.
5
Low LDL cholesterol, and genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.低密度脂蛋白胆固醇、基因变异与阿尔茨海默病和帕金森病风险：孟德尔随机化研究
BMJ. 2017 Apr 24;357:j1648. doi: 10.1136/bmj.j1648.
6
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.依洛尤单抗在 LDL 胆固醇升高的高心血管风险患者中的应用。
N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17.
7
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
8
Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis.他汀类药物治疗降低低密度脂蛋白胆固醇与新发糖尿病风险的关系：荟萃分析。
Sci Rep. 2017 Jan 10;7:39982. doi: 10.1038/srep39982.
9
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.基于肽的抗PCSK9疫苗——一种长期管理低密度脂蛋白胆固醇（LDLc）的方法。
PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014.
10
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.